Anastrozole is as effective as current breast cancer drugs with fewer side effects

Post-menopausal women taking anastrozole experienced fewer womb, ovarian and skin cancers and fewer gynaecological symptoms, according to a study led by Queen Mary University.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Conclusions: The risks of hormone therapy should be assessed on an individual basis, with consideration of age, type of hormone therapy, dose, duration of use, regimen, route, and prior exposure. Systemic hormone therapy is not recommended in breast cancer survivors, whereas vaginal low-dose estrogen appears safe. Hormone therapy may be used by endometrial, cervical, and ovarian cancer survivors with low-risk, non-estrogen-receptor–positive subtypes. Video Summary:http://links.lww.com/MENO/A516.
Source: Menopause - Category: OBGYN Tags: Review Article Source Type: research
CONCLUSIONS: Hormone replacement therapy may slightly improve overall survival in women who have undergone surgical treatment for EOC, but the certainty of the evidence is low. HRT may make little or no difference to quality of life, incidence of breast cancer, TIA, CVA and MI as the certainty of the evidence has been assessed as very low. There may be little or no effect of HRT use on progression-free survival. The evidence in this review is limited by imprecision and incompleteness of reported relevant outcomes and therefore the results should be interpreted with caution. Future well-designed RCTs are required as this is...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
This study aimed to assess the rate of ovarian failure in a large cohort of Korean premenopausal patients with breast cancer 12 months after chemotherapy. Methods: This retrospective cohort study included premenopausal women (aged 20-44 years) with breast cancer who underwent chemotherapy after surgery. The rates of treatment-related amenorrhea (TRA) and chemotherapy-induced menopause (CIM) at 12 months after chemotherapy were analyzed. Results: A total of 237 patients met the inclusion criteria. The rate of TRA was 61.6% and that of CIM was 13.1% at 12 months after chemotherapy. The rates of TRA and CIM were 28.0%...
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
Conclusions: Concerns about surgical menopause and loss of fertility are barriers to RRBSO for high-risk women despite understanding the benefits of reduced cancer risk. There is an unmet need for more information about effectively managing the noncancer consequences of RRBSO in premenopausal women. Video Summary:http://links.lww.com/MENO/A478.
Source: Menopause - Category: OBGYN Tags: Original Studies Source Type: research
Conclusion: Data showed that GnRHa may have a protective effect on young breast cancer patients regardless of HR during chemotherapy. AMH could reflect changes of OVF during chemotherapy and predict OVF after chemotherapy.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Accumulating epidemiological and molecular evidence has shown that high ‐grade serous carcinoma originates from fallopian tube secretory cells through serous tubal intraepithelial carcinoma. The changing concept of the origin of serous carcinoma has provided us a great opportunity to develop novel diagnostic and preventive approaches. AbstractOvarian cancer is the leading cause of gynecologic cancer death in the world, and its prevention and early diagnosis remain the key to its treatment, especially for high ‐grade serous carcinoma (HGSC). Accumulating epidemiological and molecular evidence has shown that HGSC origina...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: REVIEW Source Type: research
Purpose of review To delineate the current state of evidence on the impact of night shift work on age at natural menopause. Recent findings The only direct evidence is from a single observational study, which indicates that women who work night shifts are at moderately higher risk for earlier menopause and that this risk is more pronounced among younger women. Underlying biological mechanisms have yet to be sufficiently substantiated. A long-held line of inquiry, most strongly propagated by the observed link between night shift work and female breast cancer, is the ‘Light at Night’ hypothesis, which sugges...
Source: Current Opinion in Endocrinology, Diabetes and Obesity - Category: Endocrinology Tags: REPRODUCTIVE ENDOCRINOLOGY: Edited by Wendy Kuohung Source Type: research
Waseem Abbas, Ranga Raju RaoIndian Journal of Cancer 2019 56(4):293-296Adjuvant ovarian suppression, on addition to chemotherapy, reduces the risk of breast cancer in pre-menopausal women after surgery and adjuvant hormonal therapy. Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT) showed greater benefit with exemestane in high risk females in comparison to Tamoxifen. Ovarian Function Suppression (OFS) and exemestane became the standard of care, with 30% patients experiencing grade 3 and more side effects. Much higher benefit was seen in high risk group. But there are concerns about inc...
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
How can you have a moonshot trying to cure cancer and not mention people dying of cancer?I believed the narrative that is pushed on women, that if you check your breasts and if you catch it early, you’re fine.ide class="right-rail__container right-rail__container--ad"> Lianne Kraemer had been living with metastatic breast cancer for more than a year when I met her in December 2017 at the Henry B. González Convention Center in San Antonio. Throughout the week, more than 7,000 doctors, scientists and pharmaceutical-company representatives would descend on the city for the country’s most impor...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Breast Cancer health Source Type: news
Conclusion: The effects of CEE did not differ by BSO status in the overall cohort, but some findings varied by age. Among women with prior BSO, in those aged 70 years or older, CEE led to adverse effects during the treatment period, whereas women randomly assigned to CEE before age 60 seemed to derive mortality benefit over the long term. Primary Funding Source: The WHI program is funded by the National Heart, Lung, and Blood Institute; National Institutes of Health; and U.S. Department of Health and Human Services. Wyeth Ayerst donated the study drugs. PMID: 31499528 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Tags: Ann Intern Med Source Type: research
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Health | Men | Menopause | OBGYN | Ovarian Cancer | Ovaries | Skin | Study | Women